[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344426-105":59,"doc-detail-344426-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","margin-of-error-the-emerging-role-of-field-cancerization-in-predicting-recurrence-risk-of-ductal-carcinoma-in-situ","Margin of Error - The Emerging Role of Field Cancerization in Predicting Recurrence Risk of Ductal Carcinoma In Situ","","Ductal carcinoma in situ (DCIS) diagnoses are rising, yet recurrence risk prediction remains limited. Conventional histopathology and standard prognostic parameters often fail to accurately estimate local recurrence, contributing to over- or undertreatment. Margin width is also debated, motivating a shift from static, margin-based models to dynamic, patient-specific and spatially resolved diagnostic biomarkers. This review proposes field cancerization as a framework for explaining mechanisms of DCIS ipsilateral recurrence.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/margin-of-error-the-emerging-role-of-field-cancerization-in-predicting-recurrence-risk-of-ductal-carcinoma-in-situ/344426/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/margin-of-error-the-emerging-role-of-field-cancerization-in-predicting-recurrence-risk-of-ductal-carcinoma-in-situ/344426.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is recurrence prediction in DCIS still challenging?","Question",{"text":112,"@type":113},"Conventional histopathology and existing prognostic parameters often inadequately predict local recurrence. This can lead to over- or under-treatment and leaves clinical decisions constrained.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitation of margin width is discussed in the review?",{"text":117,"@type":113},"Discourse remains over the clinical implications of margin width as a measure of recurrence risk, highlighting that a margin-based model may not fully capture recurrence biology.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review propose to improve recurrence risk assessment?",{"text":121,"@type":113},"It introduces field cancerization as a dynamic, patient-specific framework and argues for spatially resolved diagnostic biomarkers. The review also calls for multivariable prognostic models using distance-mapped field biomarkers to support more precise surgery and safer de-escalation for low-risk patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344426,1790176961,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Review  \nMargin of Error: The Emerging Role of Field Cancerization in Predicting Recurrence Risk of Ductal Carcinoma In Situ  \nSophia Hu-Lieskovan 1, Olivia Banks 1, Rose Davidson 2, Dana Franklin 3, Padmashree Rida 4 and Nikita Jinna 3, *  \n1 School of Biological Sciences, University of Utah, Salt Lake City, UT 84112, USA; [u1297691@utah.edu](u1297691@utah.edu) (S.H.-L.); [olivia.banks@utah.edu](olivia.banks@utah.edu) (O.B.)  \n2 Department of Biology, Westminster University, Salt Lake City, UT 84105, USA; [mjd0531@westminsteru.edu](mjd0531@westminsteru.edu)  \n3 City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA; [dfranklin@coh.org](dfranklin@coh.org)  \n4 Science Department, Rowland Hall, Salt Lake City, UT 84102, USA; [padmashreerida@rowlandhall.org](padmashreerida@rowlandhall.org)  \n* [Correspondence: niwright@coh.org](Correspondence: niwright@coh.org)  \nAbstract  \nAlthough ductal carcinoma in situ (DCIS) diagnoses continue to climb, patient management remains constrained by limitations in recurrence prediction. Conventional histopathology and existing prognostic parameters often inadequately predict local recurrence, leading to over-or under-treatment. Additionally, discourse remains over the clinical implications of margin width as a measure of recurrence risk, demonstrating the limitations of a margin-based model, and motivating our proposal that recurrence risk is dynamic and should be defined by patient-specific, spatially resolved diagnostic biomarkers. This review introduces field cancerization as a framework that may illuminate mechanisms underlying DCIS ipsilateral recurrence and improve clinical decision-making. We propose that the potential drivers of ductal field cancerization span two stages: pre-tumorigenesis and post-tumorigenesis. Pre-tumorigenic events include non-biological and biological exposome factors. Post-tumorigenic drivers include intratumoral and microenvironmentmediated remodeling of adjacent tissues that promote malignancy. This review bridges stage-specific molecular mechanisms to potentially actionable strategies for DCIS patient management—particularly margin assessment and recurrence risk prognostication—while highlighting the critical unmet need to identify biomarkers that measure high-risk field changes. We also emphasize the need to move beyond lesion-centric management toward multivariable prognostic models that include distance-mapped field biomarkers, enabling more precise surgery, improved selection of adjuvant therapy, and safer de-escalation for low-risk patients.  \nAcademic Editors: Mario Cioce and Gatti Veronica  \nReceived: 29 January 2026  \nRevised: 2 March 2026  \nAccepted: 5 March 2026  \nPublished: 10 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nKeywords: ductal carcinoma in situ; ipsilateral recurrence; field cancerization; ductal remodeling; exosomes; tumor margin; histologically normal  \n1. Introduction  \nPrior to the early 1980s, ductal carcinoma in situ (DCIS), known then as non-invasive intraductal carcinoma, was uncommon, but treatment was straightforward. Patients were treated with a mastectomy, and the prognosis was positive [1] . However, with concerted community educational programs, advancements in screening and detection, and the advent of deep learning-based algorithms, rates of DCIS diagnoses have drastically increased in recent decades [2] . In 2022, approximately 51,400 new cases of DCIS were documented [3] .  \nThe estimate for 2024 increased to 56,600 new cases [4] . Thus, the urgency of developing effective DCIS management strategies becomes more apparent with each year.  \nSurgical resection is the current gold standard treatment for managing DCIS [5] . This treatment modality includes breast-conserving surgery (BCS) and mastectomy, depending on disease severity and stage. Alth","cbCaisoS9C80lhf1","https://ap.wps.com/l/cbCaisoS9C80lhf1","pdf",6109929,39,"English","# Abstract\n# Introduction\n## Rising DCIS incidence and treatment urgency\n## Current standards and controversy around adjuvant therapy\n## Existing recurrence-risk tools and limitations","[{\"question\":\"Why is recurrence prediction in DCIS still challenging?\",\"answer\":\"Conventional histopathology and existing prognostic parameters often inadequately predict local recurrence. This can lead to over- or under-treatment and leaves clinical decisions constrained.\"},{\"question\":\"What limitation of margin width is discussed in the review?\",\"answer\":\"Discourse remains over the clinical implications of margin width as a measure of recurrence risk, highlighting that a margin-based model may not fully capture recurrence biology.\"},{\"question\":\"How does the review propose to improve recurrence risk assessment?\",\"answer\":\"It introduces field cancerization as a dynamic, patient-specific framework and argues for spatially resolved diagnostic biomarkers. The review also calls for multivariable prognostic models using distance-mapped field biomarkers to support more precise surgery and safer de-escalation for low-risk patients.\"}]","Margin of Error - The Emerging Role of Field Cancerization in Predicting Recurrence Risk of Ductal Carcinoma In Situ | PDF",1790053726,98,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1737254fb70e9f2f6fbb5bc8ca21ed93.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e89fe8b05930bca99b713e777dd5323.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3672a609308fdb7c0e48b95c5e36979c.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5acd007be9a35dfe379cdc4d11842421.webp",980,1385]